Publicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Cardiovasculares Carlos III (351)

2024

  1. Apolipoprotein E-ϵ2 and Resistance to Atherosclerosis in Midlife: The PESA Observational Study

    Circulation Research, Vol. 134, Núm. 4, pp. 411-424

  2. Data source integration: a key tool for optimizing resources and prioritizing areas for improvement in clinical practice and epidemiology

    Revista Espanola de Cardiologia

  3. Invasive Treatment Strategy in Adults With Frailty and Non-ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of a Randomized Clinical Trial

    JAMA network open, Vol. 7, Núm. 3, pp. e240809

  4. Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines

    American Journal of Medicine, Vol. 137, Núm. 2, pp. 137-146.e10

  5. Sex-specific presentation, care, and clinical events in individuals admitted with NSTEMI: the ACVC-EAPCI EORP NSTEMI registry of the European Society of Cardiology

    European Heart Journal: Acute Cardiovascular Care, Vol. 13, Núm. 1, pp. 36-45

2023

  1. A systematic review and meta-analysis of randomized controlled trials evaluating pharmacologic therapies for acute and recurrent pericarditis

    Trends in Cardiovascular Medicine, Vol. 33, Núm. 5, pp. 319-326

  2. Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions

    Journal of the American College of Cardiology, Vol. 82, Núm. 8, pp. 687-700

  3. CASSIA (cardiology software suite for image analysis): a potential new tool for the evaluation of [18F]FDG PET/CT in the setting of infective endocarditis

    International Journal of Computer Assisted Radiology and Surgery, Vol. 18, Núm. 1, pp. 157-169

  4. Cardiac Insulin Resistance in Subjects With Metabolic Syndrome Traits and Early Subclinical Atherosclerosis

    Diabetes Care, Vol. 46, Núm. 11, pp. 2050-2057

  5. Cardiovascular and renal health: Preeclampsia as a risk marker

    Nefrologia, Vol. 43, Núm. 3, pp. 269-280

  6. Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction

    Journal of Clinical Medicine, Vol. 12, Núm. 8

  7. Current and Future Use of Artificial Intelligence in Electrocardiography

    Journal of Cardiovascular Development and Disease, Vol. 10, Núm. 4

  8. Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2

    Advanced Science, Vol. 10, Núm. 34

  9. Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years

    Journal of the American College of Cardiology, Vol. 82, Núm. 22, pp. 2069-2083

  10. Differences in clinical outcomes, health care resource utilization and costs in heart failure patients according to left ventricular ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 11, pp. 862-871

  11. Early insulin resistance in normoglycemic low-risk individuals is associated with subclinical atherosclerosis

    Cardiovascular Diabetology, Vol. 22, Núm. 1

  12. Effect of Routine Invasive vs Conservative Strategy in Older Adults With Frailty and Non-ST-Segment Elevation Acute Myocardial Infarction: A Randomized Clinical Trial

    JAMA Internal Medicine, Vol. 183, Núm. 5, pp. 407-415

  13. Exogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver

    Molecular Genetics and Metabolism Reports, Vol. 35

  14. Hereditary transthyretin amyloidosis caused by p.Ser43Asn variant. A new endemic variant in Ecuador

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 564-566

  15. Impact of standard modifiable cardiovascular risk factors on 2-year all-cause mortality: Insights from an international cohort of 23,489 patients with acute coronary syndrome

    American Heart Journal, Vol. 264, pp. 20-30